{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:39:42Z","timestamp":1791517182147,"version":"4.3.4"},"reference-count":55,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Since the release of the ICH E9(R1) (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials) document in 2019, the estimand framework has become a fundamental part of clinical trial protocols. In parallel, complex innovative designs have gained increased popularity in drug development, in particular in early development phases or in difficult experimental situations. While the estimand framework is relevant to any study in which a treatment effect is estimated, experience is lacking as regards its application to these designs. In a basket trial for example, should a different estimand be specified for each subpopulation of interest, defined, for example, by cancer site? Or can a single estimand focusing on the general population (defined, for example, by the positivity to a certain biomarker) be used? In the case of platform trials, should a different estimand be proposed for each drug investigated? In this work we discuss possible ways of implementing the estimand framework for different types of complex innovative designs. We consider trials that allow adding or selecting experimental treatment arms, modifying the control arm or the standard of care, and selecting or pooling populations. We also address the potentially data\u2010driven, adaptive selection of estimands in an ongoing trial and disentangle certain statistical issues that pertain to estimation rather than to estimands, such as the borrowing of nonconcurrent information. We hope this discussion will facilitate the implementation of the estimand framework and its description in the study protocol when the objectives of the trial require complex innovative designs.<\/jats:p>","DOI":"10.1002\/cpt.2575","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T07:58:24Z","timestamp":1646639904000},"page":"1183-1190","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Estimands and Complex Innovative Designs"],"prefix":"10.1111","volume":"112","author":[{"given":"Olivier","family":"Collignon","sequence":"first","affiliation":[{"name":"GlaxoSmithKline  Hertfordshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Schiel","sequence":"additional","affiliation":[{"name":"Norwegian Medicines Agency  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl\u2010Fredrik","family":"Burman","sequence":"additional","affiliation":[{"name":"Statistical Innovation, Data Science &amp; Artificial Intelligence AstraZeneca Research &amp; Development  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaspar","family":"Rufibach","sequence":"additional","affiliation":[{"name":"Methods, Collaboration, and Outreach Group, Product Development Data Sciences F.Hoffmann\u2010La Roche  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Posch","sequence":"additional","affiliation":[{"name":"Section for Medical Statistics Center for Medical Statistics Informatics, and Intelligent Systems Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bretz","sequence":"additional","affiliation":[{"name":"Section for Medical Statistics Center for Medical Statistics Informatics, and Intelligent Systems Medical University of Vienna  Vienna Austria"},{"name":"Novartis  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"International Council For Harmonisation of Technical Requirements For Pharmaceuticals For Human Use (ICH).ICH E9(R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials<https:\/\/database.ich.org\/sites\/default\/files\/E9\u2010R1_Step4_Guideline_2019_1203.pdf> (2019)."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2017.1302358"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7033"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-019-00063-9"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-019-00061-x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6472"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3538"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-3012-x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1804"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.05.010"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.01.001"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00717-8"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2183"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00897-7"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280219880213"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13696"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1332-x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-019-00014-4"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1723"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.33552\/ABBA.2019.01.000524"},{"key":"e_1_2_9_22_1","unstructured":"European Medicines Agency (EMA).Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design<https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/reflection\u2010paper\u2010methodological\u2010issues\u2010confirmatory\u2010clinical\u2010trials\u2010planned\u2010adaptive\u2010design_en.pdf> (2007)."},{"key":"e_1_2_9_23_1","unstructured":"US Food and Drug Administration.Guidance document: adaptive design clinical trials for drugs and biologics guidance for industry<https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/adaptive\u2010design\u2010clinical\u2010trials\u2010drugs\u2010and\u2010biologics\u2010guidance\u2010industry> (2019)."},{"key":"e_1_2_9_24_1","unstructured":"US Food and Drug Administration.Interacting with the FDA on complex innovative trial designs for drugs and biological products<https:\/\/www.fda.gov\/media\/130897\/download> (2020)."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1730"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0061"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2015.11.002"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2104"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2021.2009020"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-0697-y"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05150-7"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8194"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6407"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30111-0"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022926"},{"key":"e_1_2_9_36_1","unstructured":"EMA.Guideline on the clinical evaluation of anticancer medicinal products<https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/draft\u2010guideline\u2010evaluation\u2010anticancer\u2010medicinal\u2010products\u2010man\u2010revision\u20106_en.pdf> (2020)."},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.472"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/09622802211017574"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.08.005"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780140922"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3716"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.413"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2389"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/ast035"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12242"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280220910186"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2120"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2102446"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-01043-6"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2021.1938204"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2020.1785543"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2020.1779122"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2021.1883473"},{"key":"e_1_2_9_55_1","unstructured":"International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).ICH E9(R1) Step 2 training material<https:\/\/database.ich.org\/sites\/default\/files\/E9\u2010R1_EWG_Step2_TrainingMaterial.pdf> (2018)."},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12617"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.2575","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:36:53Z","timestamp":1699364213000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1002\/cpt.2575"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2575","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"assertion":[{"value":"2021-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}